Estimativas de analistas de Wall Street para Esperion Therapeutics, Inc. (ESPR): preço alvo de consenso, recomendações de compra/manter/venda e previsões de receita, LPA e EBITDA para os próximos exercícios.
Surpresas de Resultados Recentes
| Data | LPA Real | LPA Estimado | vs Est. |
|---|---|---|---|
| 2026-08-04 | $-0.02 | ||
| 2026-05-08 | $-0.10 | $-0.04 | -150.0% |
| 2026-03-10 | $0.22 | $0.23 | -4.3% |
| 2025-11-06 | $-0.16 | $-0.09 | -77.8% |
| 2025-08-05 | $-0.02 | $-0.17 | +88.2% |
| 2025-05-06 | $-0.21 | $-0.18 | -16.7% |
| 2025-03-04 | $-0.10 | $-0.14 | +28.6% |
| 2024-11-07 | $-0.15 | $-0.14 | -7.1% |
Índices de avaliação
| Preço / Valor contábil | -2.60 |
| EV / EBITDA | 26.29 |
| Dividend Yield | 0.00% |
Demonstração de Resultados (10 anos)
| Ano | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Receita | 0 | 0 | $184.5M | $148.4M | $227.5M | $78.4M | $75.5M | $116.3M | $332.3M | $403.1M |
| Custo da Receita | $252000 | $258000 | $265000 | 0 | $2.4M | $14.2M | $27.0M | $43.3M | $68.6M | $129.2M |
| Lucro Bruto | -$252000 | -$258000 | $184.2M | $148.4M | $225.2M | $64.2M | $48.5M | $73.1M | $263.7M | $273.9M |
| P&D | $57.9M | $147.6M | $171.5M | $175.6M | $146.9M | $106.0M | $118.9M | $86.1M | $46.2M | $47.9M |
| Despesas Gerais e Administrativas | $18.3M | $21.4M | $33.1M | $65.9M | $199.6M | $185.0M | $109.1M | $142.5M | $163.1M | $165.8M |
| Despesas Operacionais | $76.2M | $169.0M | $204.6M | $241.5M | $346.6M | $291.0M | $228.0M | $228.6M | $209.3M | $213.6M |
| Lucro Operacional | -$76.2M | -$169.0M | -$204.6M | -$93.1M | -$121.4M | -$226.7M | -$179.5M | -$155.6M | $54.4M | $60.3M |
| EBITDA | -$74.3M | -$166.5M | -$204.3M | -$88.7M | -$120.3M | -$222.1M | -$176.3M | -$150.1M | $7.6M | $63.9M |
| Despesas com Juros | $376000 | $198000 | $100000 | $8.1M | $22.7M | $46.4M | $56.8M | $59.0M | $59.3M | $84.6M |
| Lucro Antes de Impostos | -$75.0M | -$167.0M | -$201.8M | -$97.2M | -$143.6M | -$269.1M | -$233.7M | -$209.2M | -$51.7M | -$20.8M |
| Imposto | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | $1.8M |
| Lucro Líquido | -$75.0M | -$167.0M | -$201.8M | -$97.2M | -$143.6M | -$269.1M | -$233.7M | -$209.2M | -$51.7M | -$22.7M |
| LPA | $-3.33 | $-6.98 | $-7.54 | $-4.02 | $-6.05 | $-11.03 | $-4.33 | $-2.03 | $-0.28 | $-0.11 |
| LPA Diluído | $-3.33 | $-6.98 | $-7.54 | $-4.02 | $-6.05 | $-11.03 | $-4.33 | $-2.03 | $-0.28 | $-0.11 |
| Ações em Circulação (Diluídas) | $22.5M | $23.9M | $26.8M | $27.1M | $27.5M | $28.9M | $66.4M | $103.1M | $187.2M | $207.9M |
Preço
| Preço | $3.18 |
| Capitalização | $661M |
| Bolsa | NASDAQ |
| País | US |
Empresas relacionadas: AGIO · COLL · EBS · HRTX · KPTI · PTCT
Explorar setor: Healthcare · Biotechnology
Mais seções de ESPR: Resumo · Financeiros · Avaliação · Estatísticas · Técnico · Propriedade · Notícias · Eventos
Descubra mais: Radar — sinais de ações subvalorizadas · Academia de Investimento — aprenda a analisar ações